An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose

Abstract

D614G genotype of SARS-CoV-2 virus is highly infectious and responsible for almost all infection for 2 nd wave. However, there are currently no reports with D614G as vaccine candidate. Here we report the development of an mRNA-LNP vaccine with D614G variant and characterization in animal model. We have used special mRNA-architecture and formulation that provides suitable response of the product. The surface plasmon resonance (SPR) data with spike protein (S) revealed that immunization generated specific antibody pools against the whole extracellular domain (RBD and S2) of the spike protein. The anti-sera and purified IgGs from immunized mice neutralized SARS-CoV-2-pseudoviruses in ACE2-expressing HEK293 cells in a dose dependent manner. Importantly, single-dose immunization protected mice-lungs from homotypic-pseudovirus entry and cytopathy. The immunologic responses have been implicated by a balanced and stable population of CD4+ cells with a Th1 bias. The data suggested great promise for immediate translation of the technology to the clinic.

Vaccines against COVID-19 using nanotechnology: a literature review

“…analyzes were performed to discover the available protein (S) sequences of SARS-CoV-2, and a total of 15 sequences of variant D614G of 170 reference sequences of SARS-CoV-2 were found, which was also confirmed by (KORBER et al, 2020). The 'GBPD060' vaccine induced a high level of specific antibodies with a single immunization, which covers the entire length of the protein peak, suggesting that a mixture of highly relevant antibodies against these domains were developed (NAG et al, 2021).…”

“…The VLP platform is based on an aldolase (enzyme) engineered from thermophilic bacteria, spontaneously assembles into a hollow 36-nanometer dodecahedral cage with 60 subunits. The vaccine is highly immunogenic in animals, inducing robust SARS-CoV-2 neutralizing antibody responses.In the study byNag et al (2021) a vaccine called GBPD060, which uses mRNA-LNP technology specific for the D614G genotype of the SARS-CoV-2 virus, was developed and is being tested in animals. According to the author, the vaccine generated specific antibodies against SARS-CoV-2 in rats.It is encapsulated in lipid nanoparticles (LNP) with a size between 60 and 140 nm, based on mRNA encoding the 'spike' (S) glycoprotein of SARS-CoV-2 with unmodified nucleoside (unmodified molecule), stabilized in its conformation of pre-fusion (before deformation).…”

“…However, natural selection can adopt rare but convenient mutations. Since the beginning of the pandemic outbreak in China, SARS-CoV-2 has undergone numerous mutations, one of them the alteration in the amino acid D614G in the 'S' protein of the Wuhan reference strain, caused by the substitution of a nucleotide(NAG et al, 2021). Currently, D614G is considered the most prevalent circulating isotope of SARS-CoV-2 worldwide(KORBER et al, 2020).…”

“…Currently, D614G is considered the most prevalent circulating isotope of SARS-CoV-2 worldwide(KORBER et al, 2020). According toNag et al (2021), bioinformatics…”

Plant lectins as prospective antiviral biomolecules in the search for COVID-19 eradication strategies

“…To date, there are six WHO-recognized experimental vaccines available but their efficacy is still under consideration due to continuous SARS-CoV-2 mutations and wane of immunity over time. Bangladesh has also joined the global COVID-19 vaccine race with developing an mRNA-based vaccine candidate [200] with hopes for human trials in November 2021 after completion of successful clinical trials that is happening on non-human primates and monkeys [201] .…”